DK2007885T3 - Fremgangsmåde til forøgelse af in vivo-genvindingen af terapeutiske polypeptider - Google Patents
Fremgangsmåde til forøgelse af in vivo-genvindingen af terapeutiske polypeptiderInfo
- Publication number
- DK2007885T3 DK2007885T3 DK07723889.7T DK07723889T DK2007885T3 DK 2007885 T3 DK2007885 T3 DK 2007885T3 DK 07723889 T DK07723889 T DK 07723889T DK 2007885 T3 DK2007885 T3 DK 2007885T3
- Authority
- DK
- Denmark
- Prior art keywords
- therapeutic polypeptides
- enhancing
- vivo recovery
- polypeptides
- recovery
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
- C12N9/6424—Serine endopeptidases (3.4.21)
- C12N9/644—Coagulation factor IXa (3.4.21.22)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/643—Albumins, e.g. HSA, BSA, ovalbumin or a Keyhole Limpet Hemocyanin [KHL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
- C12N9/6424—Serine endopeptidases (3.4.21)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
- C12N9/6424—Serine endopeptidases (3.4.21)
- C12N9/6437—Coagulation factor VIIa (3.4.21.21)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Biophysics (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP06007552 | 2006-04-11 | ||
| PCT/EP2007/002948 WO2007115724A2 (en) | 2006-04-11 | 2007-04-02 | Method of increasing the in vivo recovery of therapeutic polypeptides |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK2007885T3 true DK2007885T3 (da) | 2010-11-08 |
Family
ID=36778259
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK07723889.7T DK2007885T3 (da) | 2006-04-11 | 2007-04-02 | Fremgangsmåde til forøgelse af in vivo-genvindingen af terapeutiske polypeptider |
Country Status (12)
| Country | Link |
|---|---|
| US (3) | US20100222554A1 (da) |
| EP (2) | EP2007885B1 (da) |
| JP (1) | JP2009533364A (da) |
| KR (1) | KR101492422B1 (da) |
| AT (1) | ATE474917T1 (da) |
| AU (1) | AU2007236280B2 (da) |
| CA (1) | CA2649199C (da) |
| DE (1) | DE602007007923D1 (da) |
| DK (1) | DK2007885T3 (da) |
| ES (1) | ES2349024T3 (da) |
| PL (1) | PL2007885T3 (da) |
| WO (1) | WO2007115724A2 (da) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1816201A1 (en) | 2006-02-06 | 2007-08-08 | CSL Behring GmbH | Modified coagulation factor VIIa with extended half-life |
| US7939632B2 (en) * | 2006-06-14 | 2011-05-10 | Csl Behring Gmbh | Proteolytically cleavable fusion proteins with high molar specific activity |
| EP3231440A1 (en) | 2006-12-22 | 2017-10-18 | CSL Behring GmbH | Modified coagulation factors with prolonged in vivo half-life |
| CN104004739A (zh) * | 2007-10-15 | 2014-08-27 | 北卡罗来纳-查佩尔山大学 | 半衰期延长的人因子ix变体 |
| CA2770609A1 (en) * | 2009-08-20 | 2011-02-24 | Csl Behring Gmbh | Albumin fused coagulation factors for non-intravenous administration in the therapy and prophylactic treatment of bleeding disorders |
| CN103140237A (zh) * | 2010-07-09 | 2013-06-05 | 比奥根艾迪克依蒙菲利亚公司 | 因子ix多肽及其使用方法 |
| EP3461905B1 (en) * | 2010-11-22 | 2020-08-05 | Amicus Therapeutics, Inc. | Novel signal sequences to improve protein expression and secretion of recombinant enzymes and other proteins |
| TW201427685A (zh) | 2012-09-25 | 2014-07-16 | Biogen Idec Inc | Fix多肽的應用 |
| EA037906B1 (ru) | 2013-03-15 | 2021-06-04 | Биовератив Терапьютикс Инк. | Препараты полипептида фактора ix |
| EP3863663A2 (en) | 2018-10-10 | 2021-08-18 | Amicus Therapeutics, Inc. | Disulfide bond stabilized polypeptide compositions and methods of use |
| US20210379203A1 (en) * | 2018-10-26 | 2021-12-09 | Vrije Universiteit Brussel | New Tools for Improving Gene Therapy and Use Thereof |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4970300A (en) * | 1985-02-01 | 1990-11-13 | New York University | Modified factor VIII |
| GR860984B (en) | 1985-04-17 | 1986-08-18 | Zymogenetics Inc | Expression of factor vii and ix activities in mammalian cells |
| US5364771A (en) * | 1992-04-07 | 1994-11-15 | Emory University | Hybrid human/porcine factor VIII |
| EP1621206A1 (en) * | 1994-12-12 | 2006-02-01 | Beth Israel Deaconess Medical Center, Inc. | Chimeric cytokines and uses thereof |
| DE19538715A1 (de) | 1995-10-18 | 1997-04-30 | Behringwerke Ag | Verfahren zur Reinigung von Faktor VII und aktiviertem Faktor VII |
| JP3735921B2 (ja) * | 1996-02-07 | 2006-01-18 | 三菱ウェルファーマ株式会社 | GPIb・脂質複合体およびその用途 |
| US6458563B1 (en) * | 1996-06-26 | 2002-10-01 | Emory University | Modified factor VIII |
| AU775422B2 (en) * | 1998-06-15 | 2004-07-29 | Gtc Biotherapeutics, Inc. | Erythropoietin analog-human serum albumin fusion |
| US6660843B1 (en) * | 1998-10-23 | 2003-12-09 | Amgen Inc. | Modified peptides as therapeutic agents |
| WO2001058935A2 (en) * | 2000-02-11 | 2001-08-16 | Maxygen Aps | FACTOR VII OR VIIa-LIKE MOLECULES |
| CA2405550A1 (en) * | 2000-04-12 | 2001-10-25 | Human Genome Sciences, Inc. | Albumin fusion proteins |
| AU2001291653A1 (en) * | 2000-10-02 | 2002-04-15 | Novo-Nordisk A/S | Industrial-scale serum-free production of recombinant factor vii in mammalian cells |
| AU1038802A (en) * | 2000-10-18 | 2002-04-29 | Maxygen Aps | Protein c or activated protein c-like molecules |
| EP1444986A1 (en) * | 2003-02-07 | 2004-08-11 | Aventis Behring GmbH | Pharmaceutical preparation for the improved treatment of blood-clotting disorders |
| TWI353991B (en) * | 2003-05-06 | 2011-12-11 | Syntonix Pharmaceuticals Inc | Immunoglobulin chimeric monomer-dimer hybrids |
| ES2339953T5 (es) * | 2004-05-04 | 2020-05-06 | Novo Nordisk Healthcare Ag | Glicoformas de factor VII ligadas a O y método de fabricación |
| EP1816201A1 (en) * | 2006-02-06 | 2007-08-08 | CSL Behring GmbH | Modified coagulation factor VIIa with extended half-life |
| US7939632B2 (en) * | 2006-06-14 | 2011-05-10 | Csl Behring Gmbh | Proteolytically cleavable fusion proteins with high molar specific activity |
| EP1867660A1 (en) * | 2006-06-14 | 2007-12-19 | CSL Behring GmbH | Proteolytically cleavable fusion protein comprising a blood coagulation factor |
| EP3231440A1 (en) * | 2006-12-22 | 2017-10-18 | CSL Behring GmbH | Modified coagulation factors with prolonged in vivo half-life |
-
2007
- 2007-04-02 DE DE602007007923T patent/DE602007007923D1/de active Active
- 2007-04-02 AT AT07723889T patent/ATE474917T1/de active
- 2007-04-02 PL PL07723889T patent/PL2007885T3/pl unknown
- 2007-04-02 WO PCT/EP2007/002948 patent/WO2007115724A2/en not_active Ceased
- 2007-04-02 ES ES07723889T patent/ES2349024T3/es active Active
- 2007-04-02 DK DK07723889.7T patent/DK2007885T3/da active
- 2007-04-02 KR KR20087027542A patent/KR101492422B1/ko not_active Expired - Fee Related
- 2007-04-02 EP EP07723889A patent/EP2007885B1/en not_active Not-in-force
- 2007-04-02 CA CA2649199A patent/CA2649199C/en not_active Expired - Fee Related
- 2007-04-02 EP EP10168156A patent/EP2263696A1/en not_active Withdrawn
- 2007-04-02 JP JP2009504607A patent/JP2009533364A/ja active Pending
- 2007-04-02 AU AU2007236280A patent/AU2007236280B2/en not_active Ceased
- 2007-04-02 US US12/226,188 patent/US20100222554A1/en not_active Abandoned
-
2013
- 2013-06-19 US US13/921,815 patent/US20130337532A1/en not_active Abandoned
-
2014
- 2014-03-27 US US14/227,397 patent/US20140248686A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| PL2007885T3 (pl) | 2010-12-31 |
| EP2007885A2 (en) | 2008-12-31 |
| US20100222554A1 (en) | 2010-09-02 |
| CA2649199A1 (en) | 2007-10-18 |
| WO2007115724A2 (en) | 2007-10-18 |
| EP2263696A1 (en) | 2010-12-22 |
| AU2007236280B2 (en) | 2013-07-25 |
| ATE474917T1 (de) | 2010-08-15 |
| KR20090008329A (ko) | 2009-01-21 |
| US20140248686A1 (en) | 2014-09-04 |
| KR101492422B1 (ko) | 2015-02-12 |
| CA2649199C (en) | 2015-01-20 |
| ES2349024T3 (es) | 2010-12-21 |
| JP2009533364A (ja) | 2009-09-17 |
| EP2007885B1 (en) | 2010-07-21 |
| WO2007115724A3 (en) | 2008-03-20 |
| AU2007236280A1 (en) | 2007-10-18 |
| US20130337532A1 (en) | 2013-12-19 |
| DE602007007923D1 (de) | 2010-09-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK2007885T3 (da) | Fremgangsmåde til forøgelse af in vivo-genvindingen af terapeutiske polypeptider | |
| CL2009001258A1 (es) | Polipeptido multivalente que comprende dos dominios de fibronectina tipo iii, ligados por un polipeptido de engarce basado en glicina-serina o glicina-prolina. | |
| MX2008002101A (es) | Fusiones de la proteina-1 quimiotactica de monocito. | |
| AR062030A1 (es) | Proteinas de fusion de exendina | |
| CY1118343T1 (el) | Αντισωματα συνδεσης twεακ | |
| DK3050963T3 (da) | Fremgangsmåde til fremstilling af polypeptid ved regulering af arrangement | |
| NZ703581A (en) | Anti-cd70 antibody drug conjugates | |
| SG171670A1 (en) | Rage fusion proteins, formulations, and methods of use thereof | |
| BRPI0813452A2 (pt) | protéinas de fusão rage. | |
| SG162687A1 (en) | Caustic stable chromatography ligands | |
| BRPI0817294A2 (pt) | Método de modificação do ponto isoelétrico de anticorpo via substituição de aminoácido em cdr. | |
| DK1773870T3 (da) | Fremgangsmåder til fremstilling af peptid, der har et C-terminalt amid | |
| MX2016011580A (es) | Dominios de fibronectina tipo iii que se unen a albumina de suero. | |
| BRPI0716744A2 (pt) | proteínas de fusão de albumina | |
| MX2012003939A (es) | Fusiones y conjugados de farmaco. | |
| IL210175A0 (en) | Fn14/trail fusion proteins | |
| EP2161287A4 (en) | OPTIMIZED TACI FC FUSION PROTEINS | |
| EA201290722A1 (ru) | Рекомбинантный белок эксендина-4 и его аналога, способ их приготовления и применение | |
| IL220164B (en) | A method for purifying a purified antibody, antibody fragment, or fc-fused protein using an affinity chromatography matrix | |
| UY31123A1 (es) | Proteinas de fusion natriureticas | |
| ATE527345T1 (de) | Chimäres fusionsprotein mit überlegenen chaperon- und faltungsaktivitäten | |
| WO2010014922A3 (en) | Protein purification tags and uses thereof | |
| WO2009025300A1 (ja) | イミュノグロブリン結合能を有するペプチド | |
| WO2009131698A3 (en) | PHOSPHORYLATED RECOMBINANT N-ACETYL-alpha-D- GLUCOSAMINIDASE (NaGlu) AND USES THEREOF | |
| CY1116757T1 (el) | Πεπτιδια που προσδενουν υποδοχεα αυξητικου παραγοντα 1 ομοιαζοντος με ινσουλινη |